Last reviewed · How we verify
NCT05717751
Predictors of Para-aortic Lymph Node Metastasis of Cervical Cancer
trial testing surgical staging in Locally Advanced Cervical Cancer in 452 participants. Completed in 12 December 2022.
12 November 2022
Quick facts
| Lead sponsor | Chongqing University Cancer Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 452 |
| Start date | 13 April 2022 |
| Primary completion | 12 November 2022 |
| Estimated completion | 12 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- surgical staging
Conditions studied
- Locally Advanced Cervical Cancer — all drugs for Locally Advanced Cervical Cancer →
Sponsor
Chongqing University Cancer Hospital
Who can join
Adults 18 to 75, female only, with Locally Advanced Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to identify predictive factors and to develop a risk model predicting para-aortic lymph node metastasis in patients with locally advanced cervical cancer based on the analysis of surgical staging results. The main questions it aims to answer are: * What are the risk factors to predict para-aortic lymph node metastasis in patients with locally advanced cervical cancer? * What is the indication for prophylactic extended-field radiation therapy in patients with locally advanced cervical cancer Individual data of patients with locally advanced cervical cancer treated with surgical staging at our institution from 2020 to 2022 were pooled analysed.Multivariate Logistic regression analysis was used to identify the predictive factors and to develop the prediction model.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05717751
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of surgical staging
Trials testing the same drug.
- NCT06068387 — A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis · NA · unknown
- NCT04570553 — Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Canc · NA · recruiting
Other recruiting trials for Locally Advanced Cervical Cancer
Currently open trials in the same condition.
- NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
- NCT07055399 — Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) · Phase 2 · recruiting
- NCT06943833 — A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) · Phase 2 · active not recruiting
- NCT07205497 — QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer · Phase 2 · active not recruiting
- NCT07104149 — Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer · Phase 2 · recruiting
Other Chongqing University Cancer Hospital trials
Trials by the same sponsor.
- NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
- NCT07425795 — Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of E · Phase 2 · recruiting
- NCT07248696 — Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Pro · NA · active not recruiting
- NCT07248670 — Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC · Phase 3 · active not recruiting
- NCT06981858 — A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advan · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05717751 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing University Cancer Hospital
- Last refreshed: 8 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05717751.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing